Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to ...

Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, its strong top-line performance caught investor attention. Amgen’s total ...

WASHINGTON, March 17 (Reuters) - Amgen Inc's Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clear clinical benefit beyond its ...